vs
Side-by-side financial comparison of Civeo Corp (CVEO) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Civeo Corp is the larger business by last-quarter revenue ($161.6M vs $92.9M, roughly 1.7× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs -4.0%, a 29.0% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 7.1%). Civeo Corp produced more free cash flow last quarter ($14.5M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -1.4%).
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CVEO vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $161.6M | $92.9M |
| Net Profit | $-6.5M | $23.2M |
| Gross Margin | 22.7% | 78.7% |
| Operating Margin | -0.1% | 24.1% |
| Net Margin | -4.0% | 25.0% |
| Revenue YoY | 7.1% | 23.3% |
| Net Profit YoY | 58.1% | 17.3% |
| EPS (diluted) | $-0.58 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $161.6M | $92.9M | ||
| Q3 25 | $170.5M | $67.5M | ||
| Q2 25 | $162.7M | $63.2M | ||
| Q1 25 | $144.0M | $52.6M | ||
| Q4 24 | $151.0M | $75.4M | ||
| Q3 24 | $176.3M | $57.9M | ||
| Q2 24 | $188.7M | $52.7M | ||
| Q1 24 | $166.1M | $51.3M |
| Q4 25 | $-6.5M | $23.2M | ||
| Q3 25 | $-455.0K | $5.1M | ||
| Q2 25 | $-3.3M | $-553.0K | ||
| Q1 25 | $-9.8M | $-11.2M | ||
| Q4 24 | $-15.4M | $19.8M | ||
| Q3 24 | $-5.1M | $-901.0K | ||
| Q2 24 | $8.2M | $-4.7M | ||
| Q1 24 | $-5.1M | $-3.9M |
| Q4 25 | 22.7% | 78.7% | ||
| Q3 25 | 25.7% | 73.5% | ||
| Q2 25 | 25.3% | 73.7% | ||
| Q1 25 | 20.4% | 69.0% | ||
| Q4 24 | 18.6% | 77.6% | ||
| Q3 24 | 21.4% | 71.9% | ||
| Q2 24 | 25.4% | 69.5% | ||
| Q1 24 | 21.5% | 68.9% |
| Q4 25 | -0.1% | 24.1% | ||
| Q3 25 | 4.1% | 5.1% | ||
| Q2 25 | 1.7% | -3.2% | ||
| Q1 25 | -3.8% | -24.3% | ||
| Q4 24 | -6.7% | 24.5% | ||
| Q3 24 | 0.0% | -4.3% | ||
| Q2 24 | 6.9% | -11.5% | ||
| Q1 24 | -1.1% | -10.7% |
| Q4 25 | -4.0% | 25.0% | ||
| Q3 25 | -0.3% | 7.5% | ||
| Q2 25 | -2.0% | -0.9% | ||
| Q1 25 | -6.8% | -21.4% | ||
| Q4 24 | -10.2% | 26.3% | ||
| Q3 24 | -2.9% | -1.6% | ||
| Q2 24 | 4.4% | -8.9% | ||
| Q1 24 | -3.1% | -7.5% |
| Q4 25 | $-0.58 | $0.46 | ||
| Q3 25 | $-0.04 | $0.10 | ||
| Q2 25 | $-0.25 | $-0.01 | ||
| Q1 25 | $-0.72 | $-0.23 | ||
| Q4 24 | $-1.04 | $0.40 | ||
| Q3 24 | $-0.36 | $-0.02 | ||
| Q2 24 | $0.56 | $-0.10 | ||
| Q1 24 | $-0.35 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $174.4M | $354.6M |
| Total Assets | $477.4M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $137.5M | ||
| Q3 25 | $12.0M | $135.4M | ||
| Q2 25 | $14.6M | $116.9M | ||
| Q1 25 | $28.4M | $112.9M | ||
| Q4 24 | $5.2M | $116.2M | ||
| Q3 24 | $17.9M | $101.7M | ||
| Q2 24 | $7.4M | $102.5M | ||
| Q1 24 | $16.8M | $110.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $174.4M | $354.6M | ||
| Q3 25 | $182.5M | $321.9M | ||
| Q2 25 | $209.4M | $306.8M | ||
| Q1 25 | $220.7M | $295.5M | ||
| Q4 24 | $236.4M | $292.0M | ||
| Q3 24 | $282.2M | $257.5M | ||
| Q2 24 | $297.4M | $243.0M | ||
| Q1 24 | $297.4M | $233.9M |
| Q4 25 | $477.4M | $488.0M | ||
| Q3 25 | $491.1M | $453.3M | ||
| Q2 25 | $508.8M | $435.6M | ||
| Q1 25 | $423.8M | $424.6M | ||
| Q4 24 | $405.1M | $432.7M | ||
| Q3 24 | $477.6M | $390.4M | ||
| Q2 24 | $483.2M | $376.8M | ||
| Q1 24 | $513.1M | $356.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | $15.0M |
| Free Cash FlowOCF − Capex | $14.5M | $12.8M |
| FCF MarginFCF / Revenue | 8.9% | 13.8% |
| Capex IntensityCapex / Revenue | 3.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | $15.0M | ||
| Q3 25 | $13.8M | $22.1M | ||
| Q2 25 | $-2.3M | $8.2M | ||
| Q1 25 | $-8.4M | $6.6M | ||
| Q4 24 | $9.5M | $22.2M | ||
| Q3 24 | $35.7M | $10.2M | ||
| Q2 24 | $32.4M | $18.5M | ||
| Q1 24 | $6.0M | $7.2M |
| Q4 25 | $14.5M | $12.8M | ||
| Q3 25 | $8.2M | $19.5M | ||
| Q2 25 | $-6.8M | $81.0K | ||
| Q1 25 | $-13.7M | $-7.6M | ||
| Q4 24 | $1.8M | $8.5M | ||
| Q3 24 | $28.2M | $-9.2M | ||
| Q2 24 | $27.0M | $1.8M | ||
| Q1 24 | $372.0K | $-6.8M |
| Q4 25 | 8.9% | 13.8% | ||
| Q3 25 | 4.8% | 28.8% | ||
| Q2 25 | -4.2% | 0.1% | ||
| Q1 25 | -9.5% | -14.5% | ||
| Q4 24 | 1.2% | 11.2% | ||
| Q3 24 | 16.0% | -15.9% | ||
| Q2 24 | 14.3% | 3.4% | ||
| Q1 24 | 0.2% | -13.3% |
| Q4 25 | 3.0% | 2.4% | ||
| Q3 25 | 3.3% | 3.9% | ||
| Q2 25 | 2.8% | 12.9% | ||
| Q1 25 | 3.7% | 27.0% | ||
| Q4 24 | 5.1% | 18.3% | ||
| Q3 24 | 4.2% | 33.5% | ||
| Q2 24 | 2.8% | 31.8% | ||
| Q1 24 | 3.4% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVEO
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
